Given the need to evaluate therapeutic methods to safely boost endogenous CNS oxytocin signaling in patients with ASD, combined with the clear high rates of gastrointestinal dysregulation in individuals with autism, we proposed to evaluate the safety of oral administration of SB-121 in adolescents and adults with autism. Here, OXT is linked to autism.